Analytical interference with most current commercial HIV molecular assays in patients treated by idecabtagene vicleucel, a recently approved lentivirus-based chimeric antigen receptor T-cell therapy - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Clinical Microbiology and Infection Année : 2023

Analytical interference with most current commercial HIV molecular assays in patients treated by idecabtagene vicleucel, a recently approved lentivirus-based chimeric antigen receptor T-cell therapy

Fichier principal
Vignette du fichier
Pronier et al-2023-Analytical interference with most current commercial HIV molecular assays in patients treated by idecabtagene vicleucel.pdf (221.61 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Licence : CC BY NC - Paternité - Pas d'utilisation commerciale

Dates et versions

hal-04313603 , version 1 (22-02-2024)

Identifiants

Citer

Charlotte Pronier, Karl Stefic, Helene Le Guillou-Guillemette, Mikaël Roussel, Vincent Thibault, et al.. Analytical interference with most current commercial HIV molecular assays in patients treated by idecabtagene vicleucel, a recently approved lentivirus-based chimeric antigen receptor T-cell therapy. Clinical Microbiology and Infection, 2023, Clinical Microbiology and Infection : the Official Publication of the European, 30 (2), pp.258-260. ⟨10.1016/j.cmi.2023.10.026⟩. ⟨hal-04313603⟩
9 Consultations
2 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More